Fosfomycin Calcium Market to reach $485 million by 2030; growing incidence of antibiotic resistance, the increase in HAIs, increasing prevalence of multi-drug resistant bacteria, increase in the R&D field with combination therapies along with the gro

The Fosfomycin Calcium Market size is estimated to reach $485 million by 2030, growing at a CAGR of 6.0% during the forecast period 2024-2030, according to a recent report published by IndustryARC, titled, “Fosfomycin Calcium Market - By Source (Natural, Synthetic), By Form (Tablet, Capsule, Injection), By Application (Urinary Tract Infections, Endocarditis, Ventilator–Associated Pneumonia, Bacterial Meningitis, Bacteremia, Chemotherapy, Others), By End User (Hospitals, Ambulatory Surgical Centers, Specialized Clinics), By Geography - Global Opportunity Analysis & Industry Forecast, 2024-2030.”

The rise of antibiotic-resistant bacteria is a major concern in healthcare. Fosfomycin Calcium's effectiveness against some resistant strains positions it as a valuable alternative treatment. Unlike many antibiotics, Fosfomycin Calcium disrupts bacterial cell wall formation in a unique way. This can be beneficial for treating infections caused by bacteria resistant to other antibiotics.

The Asia Pacific region dominates the Fosfomycin calcium market due to the need for antibiotics in the region as well as increasing burden of disease. Moreover, bacterial infections and rapidly increasing antibiotic resistance rates also drive the demand. According to a report published in 2024 by the Indian Council of Medical Research (ICMR), drug-resistant and difficult to treat urinary tract infections (UTIs), blood stream infections, pneumonia and typhoid are among the diseases in India that are showing resistance to commonly used antibiotics. Apart from India, several countries in the region face growing healthcare challenges associated with antibiotic resistance driving demand for effective alternatives like fosfomycin calcium. Additionally, the expanding healthcare infrastructure and greater awareness about antibiotic stewardship in this region amplify demand.

The growing prevalence of multi-drug resistant bacteria (MDRB) is a major driver for the fosfomycin calcium market. MDRB poses a significant challenge to public health globally. Antibiotic resistance is recognised as a global threat to human health by national healthcare agencies, governments and medical societies as well as the World Health Organization. Increasing resistance to available antimicrobial agents is of concern for bacterial, fungal, viral and parasitic pathogens. One of the greatest concerns is the continuing escalation of antimicrobial resistance among Gram-negative bacteria resulting in the endemic presence of multidrug-resistant (MDR) and extremely drug-resistant (XDR) pathogens. The European Respiratory Review terms this as a silent pandemic. This crisis prompts heightened demand for broad-spectrum antibiotics like fosfomycin that can tackle resistant strains effectively. Hospitals, which are key environments for the spread of MDRB, are increasingly incorporating fosfomycin calcium into their treatment protocols to combat infections that other antibiotics fail to address. As healthcare providers face mounting pressure to manage infections in immunocompromised patients, fosfomycin’s efficacy against challenging strains has made it a valuable resource in resistance management.

The prevalence of hospital-acquired infections (HAIs) is boosting the demand for fosfomycin calcium as healthcare facilities seek effective solutions to mitigate infection spread. HAIs are a persistent issue in hospitals often involving resistant bacteria strains that are challenging to treat with conventional antibiotics. The World Health. Organization (WHO) estimates that approximately 15% of hospitalized patients get HAIs. Fosfomycin calcium is recognized for its broad-spectrum activity and effectiveness in such high-risk environments, helping healthcare providers manage and reduce the incidence of HAIs. As hospitals intensify efforts to reduce patient infection rates, fosfomycin calcium has become a valuable asset, particularly in treating vulnerable populations, such as those with compromised immune systems.

Key companies profiled in the Fosfomycin Calcium Market are 

Diabetes Injection Pens Market – The Diabetes Injection Pens Market Size is estimated to reach $11.2 billion by 2028 and it is poised to grow at a CAGR of 6.1% over the forecast period of 2023-2028. Diabetic patients use an insulin pen or injection pen to regulate insulin. It is an easy and convenient way of taking insulin doses through an injection.

Human Insulin Market - Human Insulin Market size is forecast to reach $27.81 billion by 2025, growing at a CAGR of 5.40% during the forecast period 2020-2025. Insulin is a peptide hormone, secreted in the pancreas by beta cells of the islets of Langerhans, and it helps to regulate glucose metabolism.

Alzheimer’s Drugs Market - Alzheimer’s Drugs Market size in 2019 is estimated to be $3.5 billion, growing at a CAGR of 6.8% during the forecast period 2020-2025. Increasing prevalence of the neurological disorder in the geriatric population and rising aging population across the globe are the major factors driving the growth of the market.